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Abstract
Abdominal aortic aneurysms (AAAs) are encountered by many healthcare 
providers such as interventional radiologists, vascular surgeons, cardiologists, 
and general practitioners. Much effort has been placed in the screening, diagnosis, 
and treatment of AAA with somewhat little understanding of its pathophysiology. 
AAA is a complex disease typically segmented into a process of proteolysis, inflam-
mation, and vascular smooth muscle cell (VSMC) apoptosis with oxidative stress 
balancing its components. AAA and other aortic syndromes such as aortic dissec-
tion share this same process. On the other hand, AAA formation and aortic pathol-
ogy may be acquired through infection like in mycotic aneurysm or may be genetic 
in origin such as seen with Ehlers-Danlos and Marfan syndromes.
Keywords: abdominal, aortic, aneurysm, dissection, mycotic, atherosclerosis, 
proteolysis, inflammation, oxidative stress, VSMC apoptosis, Marfan, Ehlers-Danlos, 
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1. Introduction and background of AAA
Abdominal aortic aneurysm (AAA) is a complex disease comprised of multifac-
torial molecular processes that carry a host of players yet to be solidified in litera-
ture. Although options continue to expand in the treatment of AAA, understanding 
the pathophysiology is pivotal for the development of screening tests and pharma-
cological treatment modalities.
In this chapter, we will go beyond the clinical context of AAA and discuss the 
various pathologic pathways that lead to its creation. Some of these pathways 
overlap with other aortic pathologies such as aortic dissection as well as mycotic 
aneurysm. Lastly, we will discuss common genetic disorders that are predisposed to 
aortic aneurysm and aortic dissection.
2. Abdominal aortic aneurysm
2.1 Normal anatomy and histology
The aorta is the main artery of the body that carries oxygenated blood from the 
heart to the remaining major arteries of the body. It may be segmented into the tho-
racic aorta and abdominal aorta based on its location to the diaphragmatic hiatus.
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There are three sheaths that make up the aortic wall: tunica intima, tunica 
media, and tunica adventitia. The intimal layer is thin and mainly composed of 
endothelial cells, while the tunica media is the largest component of the aortic 
wall and consist of elastic fibers, smooth muscle cells, and collagenous tissue. 
Connective tissue makes up the most outer layer called the tunica adventitia and 
contains small blood vessels known as the vasa vasorum, which supply the cells of 
the arterial wall.
An aneurysm is defined as the localized dilatation of a vessel exceeding 1.5 times 
the normal diameter of the vessel, which is defined as greater than 3 cm in the 
abdominal aorta. As the abdominal aorta dilates, it becomes prone to rupture or tear-
ing within the layers of its wall, otherwise known as aortic dissection (AD). In AAA 
and AD, patients may present with low blood pressure and a tearing sensation in the 
chest or back. When blood rushes into the medial layer forming a new, “false” lumen, 
further expansion can compress the “true” lumen causing downstream ischemia.
2.2 Role of aortic atherosclerosis
Atherosclerosis is often present in the setting of aortic pathology and although no 
causal pathway has been established, understanding the bridge between atheroscle-
rosis and the inflammatory response in AAA remains essential. Early atherogenesis 
begins with subendothelial retention of circulating lipoproteins on proteoglycans 
within the extracellular matrix of the arterial wall. Aggregation and oxidation of 
retained lipoproteins further leads to a maladaptive immune response with circulat-
ing monocytes entering the subendothelium, differentiating into macrophages, 
ingesting the modified lipoproteins, and transforming into the classic “foam cell.” 
The release of cytokines in this process, such as tumor necrosis factor-α (TNF-α) 
and interferon-γ (IFN-γ), leads to immune cell infiltration and inflammation [1, 2].
2.3 Pathogenesis of abdominal aortic aneurysm
Much of our understanding of AAA until this point arises from histopathologi-
cal studies dating back to 1972 when the “Inflammatory” variant of AAA was 
described [3]. Since then, the most prevalent features of studied AAA segments 
have demonstrated elastin degeneration, immune cell infiltration, and apoptosis 
of vascular smooth muscle cells (VSMCs). Although the complete pathogenesis is 
unknown, information from animal models, histopathological studies and genome-
wide association studies (GWAS) may be used to partition this intricate process 
into proteolysis, inflammation, and vascular smooth muscle cell (VSMC) apoptosis. 
Oxidative stress appears to be a major player as well and balances different facets of 
AAA development and growth.
2.3.1 Proteolysis
During aneurysmal growth, significant proteolytic degradation of elastin, 
collagen, laminin, fibronectin, and many other extracellular matrix (ECM) proteins 
occurs in the arterial wall. Upregulation of proteolytic enzymes in the aortic wall 
is stimulated by the presence of oxidized LDL and cytokines such as TNF-α, IL-1, 
and IL-3 [4]. The most famous set of proteolytic enzymes are known as the matrix 
metalloproteinases (MMPs), which have been implicated in cancer, wound healing, 
and many other processes. During normal homeostasis, regulation of MMPs in the 
aortic wall is carried out by tissue inhibitors of MMPs (TIMPs), but a higher MMP/
TIMP ratio is typically observed in aneurysms [5, 6].
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Of the multiple MMPs, MMP-9 and MMP-2 are considered crucial participants 
in AAA and aortic dissection (AD) development, both significantly upregulated 
in AAA segments with MMP-9 expression correlating with aneurysm diameter. 
MMP-9 is derived from macrophages and neutrophils and MMP-2 is produced by 
smooth muscle cells and fibroblasts; together, they both balance ECM remodel-
ing, inflammation, and VSMC apoptosis through various signaling pathways such 
as the MAPK (mitogen-activated protein kinase)/ERK pathway [7]. TGF-beta 
signaling pathways help balance MMP-2 and MMP-9 in addition to creating protec-
tion against AAA formation by increasing type I and III collagen production and 
upregulating protease inhibitors [8].
2.3.2 Inflammation
Innate and adaptive arms of the immune system are involved in the develop-
ment and growth of AAA. Neutrophil infiltration and release of elastase induces 
early degradation of the ECM in the aortic wall. Elastin breakdown products 
trigger either pro-inflammatory or anti-inflammatory macrophages in the 
adventitial layer of the aortic wall. T-cell derived interferon gamma and B cells 
are also involved in AAA formation. B cells provide a source of immunoglobu-
lins, complement pathway, and cytokines, which add to the complexity of AAA 
formation [9–11].
2.3.3 VSMC apoptosis
Necrosis and apoptosis have traditionally been deemed different mechanisms 
[12]. Apoptosis is considered an organized and instructed route of cell death while 
necrosis is regarded as an unorganized disruption of a cell with an additional 
immune response. With this in mind, VSMC apoptosis occurring in the tunica 
media of the aortic wall in AAA formation is not a recent discovery, although the 
exact phenomenon is not known.
In addition to a review on cell death nomenclature, Wang et al. describe recep-
tor-interacting protein kinase 3 (RIP3) on VSMCs as a key player in a structured 
form of necrosis, also known as necroptosis [12]. It is believed that RIP3 mediating 
inflammatory cytokine production by smooth muscle cells is mediated in the aortic 
wall through TNF-α signaling pathways. Additionally, protein kinase C-delta (PKC) 
is upregulated in aneurysmal tissues which lack VSMCs and murine models have 
demonstrated decreased RIP3 levels in aortic tissue that lacks PKC, further validat-
ing the role of PKC in AAA formation [13, 14].
2.4 Oxidative stress
2.4.1 Defining oxidative stress
Oxidative stress is defined as cellular injury induced by reactive oxygen species 
(ROS) and reactive nitrogen species (RNS), taken as a combined ROS/RNS system 
[15]. Pathologic oxidative stress to the vasculature occurs via a multi-faceted, highly 
complex mechanism that is thought to occur in part by the ROS/RNS system. The 
ROS/RNS system is defined as a group of molecules consisting of free radicals or 
molecules which predispose to free radical formation. A free radical is any species 
that contains one or more unpaired electrons that is capable of existing indepen-
dently, which makes them highly unstable and will react readily with lipids, cellular 
proteins, and nucleic acids [15, 16].
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2.4.2 Normal pathophysiology and regulation
The production of ROS/RNS is highly regulated and occurs naturally to some 
degree in all normal cells due to the incomplete reduction of molecular oxygen 
to water during cellular respiration and within phagosomes of phagocytic cells 
(chiefly neutrophils and macrophages) [15]. ROS/RNS are typically short-lived, 
owing to their instability and prompt removal/inactivation by endogenous cellular 
antioxidants and antioxidant enzymes such as catalase, glutathione peroxidase, and 
superoxide dismutase. Dysregulation occurs when ROS/RNS production exceeds 
clearance.
2.4.3 The various ROS/RNS entities and their chemical reactions
The principal ROS/RNS involved in cellular injury include superoxide, 
hydrogen peroxide, hydroxyl radicals, and peroxynitrite. These entities medi-
ate vascular damage either directly or indirectly by conversion to more reactive 
substances [15, 16].
a. Hydrogen peroxide. Hydrogen peroxide (H2O2) is the most abundant non-radical 
oxidant and is formed mostly from superoxide dismutase acting on superoxide 
radicals [16]. In and of itself it is stable in configuration, weakly oxidizing, and 
can cross cellular membranes. In the presence of transitional metallic elements 
such as iron (Fe), hydrogen peroxide can decompose into a highly reactive and 
unstable hydroxyl radical (OH) in a process known as the Fenton reaction. 
In the Fenton reaction, peroxide is removed via conversion to H2O and O2 via 
catalase and glutathione peroxidase. Furthermore, hydrogen peroxide can be 
broken down into far more reactive species. For example, hydrogen peroxide 
will react with NO to form peroxynitrite (ONOO−), a potent mediator of 
vascular damage. Peroxynitrite causes inactivation of enzymes by oxidation 
and nitration, MMP induction with subsequent vascular connective tissue 
breakdown, and lipid peroxidation [15–17].
b. NADPH oxidase. NADPH oxidase, also known as “Phagocyte Oxidase,” is a 
well-known enzyme encoded by the NOX gene family. The NOX family is made 
up of multiple protein subunits that collectively oxidize nicotaminide-adenine 
dinucleotide phosphate (NADPH) to reduce molecular dioxygen (O2) into 
the superoxide anion (O2
•−) [15, 16]. In combination with myeloperoxidase 
and other enzymes, NADPH oxidase is required in the oxidative destruction 
of microbes via phagocytosis, classically known as the “respiratory burst.” In 
comparison to the oxidative stress in AAA, the respiratory burst occurs within 
the contents of a phagolysosome, so the host cell contents are protected from 
the ROS that are generated. Since phagocytic cells such as macrophages are also 
strongly implicated in the inflammatory response associated with pathology 
of the aortic vessel wall, it follows that membrane-bound NADPH oxidase has 
been suggested as one of the predominant sources of vascular ROS linked to 
oxidative stress in aortic pathologies such as AAA and AD [18–20].
c. The hydroxyl radical is produced by a variety of chemical reactions involving 
H2O2, H2O, and O2
•−. The hydroxyl radical is highly reactive and will readily react 
with virtually any biomolecule it encounters in a short diffusion distance (about 
the diameter of the typical protein) [16]. It is removed via conversion to H2O via 
glutathione peroxidase and has direct damaging effects on lipoproteins and DNA.
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2.4.4 Reactive nitrogen species
In addition to ROS, reactive nitrogen species (RNS) also play a role in the 
pathophysiology of vascular dysfunction. Nitric oxide (NO) is produced via an 
l-arginine precursor by nitric oxide synthases with multiple cofactors. Encoded 
isozymes of mammalian NOS include endothelial, neuronal, and inducible subtypes 
(eNOS, nNOS, and iNOS, respectively). Endothelial homeostasis rests firmly upon 
tight regulation of endogenous NO production, but pathologic uncoupling of NOS 
isozymes or IFN-γ mediated NO production by macrophages can lead to excess NO 
and/or ROS. Peroxynitrite (ONOO−), a powerful non-radical nitrosative stressor, is 
formed by the reaction of O2
•− and NO and serves as the basis for other RNS deriva-
tives such as nitrogen dioxide (NO2) [16, 17].
Peroxynitrite is a highly reactive proatherogenic mediator and readily reacts 
with protein side chains and carbon dioxide to cause cellular injury [16]. A notable 
example is 3-nitrotyrosine, formed by the reaction of peroxynitrite with tyrosine, 
which has been suggested as a local marker of oxidative stress in immunostained 
samples of aneurysmal aortas [19]. Additionally, Kotlarczyk et al. revealed a path-
way consisting of oxidative and hemodynamic stress on the aortic wall leading to 
increased superoxide production and NO bioavailability. This linkage corresponded 
to an increased rate of asymmetric thoracic aorta dilatation in patients with bicus-
pid aortopathy versus their tricuspid counterparts [20].
2.4.5 Role of oxidative stress in aortic pathology
The role of oxidative stress in the pathogenesis of aortic pathologies such as 
aortic aneurysm involves pathologic vascular remodeling along with dysfunctional 
balancing of connective tissue breakdown and synthesis by VSMCs [19–21]. This is 
thought to occur due to several mechanisms, including ROS/RNS induced VSMC 
apoptosis and enhanced matrix metalloproteinase (MMP) activity, which leads to 
progressive weakening of the aortic wall, dilatation, and eventual aneurysm forma-
tion via the breakdown of collagen, elastin, and laminin. Oxidative stress is a major 
modulator of MMP formation and can disrupt the corresponding balance of TIMPs 
that are otherwise crucial to the structural integrity of the extracellular matrix of 
the arterial wall [21, 22].
Additionally, ROS can disrupt VSMC proliferation via a mechanism linked to 
the relative local redox microenvironment concentrations of hydrogen peroxide 
and lipid hydroperoxides [16, 18, 23]. Hydrogen peroxide is involved in various 
pathways and serves as a mediator of vascular inflammation, upregulating various 
chemotactic and adhesion molecules such as ICAM-1, IL-8, and P-selectin which 
facilitate leukocyte migration into the aortic wall. In a study of patients undergo-
ing elective infrarenal AAA repair, tissue samples of aneurysmal aortic segments 
demonstrated superoxide levels 2.5 times that of adjacent non-aneurysmal aortic 
segments, as well as increased expression and activity of NADPH oxidase [18]. In 
addition, changes in normal local blood flow hemodynamics in aneurysmal aortas 
may also induce ROS production and contribute to aortic remodeling and dissection 
[20, 24, 25].
Xanthine oxidoreductase (XOR) is a famous complex molybdoflavin protein 
known to healthcare providers as a catalyzer in the terminal steps of purine degra-
dation, and when therapeutically inhibited, a target for treatment of hyperuricemia 
and gout. Although XOR may be involved in the pro-inflammatory state associated 
with crystal formation in gout, it may have an antioxidant role when under the 
optimal conditions, which necessitates further studies [26].
Cardiovascular Risk Factors in Pathology
6
2.5 Aortic dissection
Similar to AAA, the physiology of aortic dissection (AD) entails a complex 
multifactorial process consisting of proteolysis, inflammation, and VSMC apoptosis. 
The differentiating factor is that hemodynamic stress results in intimal tearing of the 
aortic wall allowing blood to rush into the medial layer. This process creates a “true” 
and “false” lumen that may propagate in either direction to occlude the true lumen 
and/or cause a variety of issues resulting in significant morbidity and mortality.
2.6 Mycotic aneurysm
A mycotic aortic aneurysm is characterized by a local, irreversible dilatation of the 
aorta which is secondary to a direct bacterial or fungal inoculation of the vessel wall. 
The term mycotic aneurysm is actually a misnomer, as these “infective” aneurysms 
are most commonly bacterial in nature and fungal to a lesser extent. Staphylococcus 
and Salmonella species are the two most commonly cultured organisms in mycotic 
aneurysms, however, improved bacteriologic techniques have led to the detection of 
anaerobic bacteria (mostly Bacteroides, and Clostridium spp.). Mycotic aneurysms 
are rare as they only represent 1–2.6% of all aortic aneurysms [27, 28].
The formation of mycotic aneurysms is initiated by a microbial induced pro-
inflammatory cascade of cytokines, such as TNF-α, IL-1, IL-6, invading the aortic 
vessel wall [28]. The recruitment of inflammatory cells within the vessel causes 
functional changes to VSMCs and endothelial cells with subsequent loss of integrity 
in the tunica media. This intense cytokine cascade causes mycotic aneurysms to 
progress more rapidly and aggressively than inflammatory aneurysms and thus 
have a higher mortality rate when compared [29].
Mycotic aneurysms most commonly affect diseased aortic endothelium in the 
setting of bacteremia and may present as nonspecific back pain or abdominal pain 
depending on the location of the lesion. Patients will typically be febrile, indicating 
a systemic infection, and lab values will show signs of leukocytosis and elevated 
ESR. Importantly, Gram negative organisms tend to cause a more virulent arterial 
infection than Gram positive bacteria, which makes the resultant aneurysm even 
more prone to rupture and further increases the risk of mortality [30–32].
Treatment of mycotic aneurysm focuses on empiric antibiotic therapy while 
waiting for blood culture susceptibility panel with individualized duration, surgi-
cal excision with wide debridement of infected tissues, and revascularization as 
needed.
2.7 Screening and diagnosis of AAA
The primary role of AAA screening and surveillance is mortality reduction, pri-
marily through one-time and/or periodic non-invasive imaging. The initial workup 
of any aortic pathology begins with a focused history and physical examination. 
Classically, AAA may present with a pulsatile epigastric abdominal mass, but many 
patients are asymptomatic and lack this finding. However, the physical exam may 
assist in identifying more distal aneurysmal disease, particularly those occurring in 
the femoropopliteal distribution, which may be predictive of coexisting AAA. The 
physical examination is also crucial to determine a patient’s baseline status in terms 
of perioperative risk with regards to a future surgical or endovascular intervention 
[33]. A number of serum biomarkers and genetic factors are known to be associated 
with AAA, and despite being an exciting area of developing research, the prognostic 
and diagnostic value of these factors has not yet been validated clinically, and there-
fore do not yet play a significant role in the diagnosis and management of AAA [33].
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2.7.1 Screening
Ultrasound (US) and computed tomography (CT) angiography are the two 
primary imaging modalities used for AAA and are both highly accurate and repro-
ducible. Transabdominal US is relatively inexpensive and can be performed in 
minutes without the use of ionizing radiation or iodinated contrast media. US car-
ries a sensitivity and specificity approaching 100% in asymptomatic patients with 
AAA, making it the modality of choice for AAA screening and surveillance. Both 
the Society for Vascular Surgery (SVS) and the US Preventive Services Task Force 
(USPSTF) recommend a one-time screening ultrasound for AAA in men or women 
65–75 years of age with a history of tobacco use [33, 34]. Various additional recom-
mendations exist for that of first-degree relatives of those presenting with AAA, 
follow-up US examinations based on initial aortic diameter at initial screening, and 
screening in non-smokers or females, but these recommendations are supported 
by lower-level data or are of unclear benefit. Obesity, overlying bowel gas, and user 
dependence are recognized limitations ultrasound evaluation for AAA, and US 
may underestimate AAA size by 2 mm [33, 34]. However, limitations are invariably 
offset by the aforementioned benefits, and US can be useful evaluating other causes 
of abdominal pain, particularly in the emergent setting, resulting in a reduction 
in time to diagnosis and treatment. When AAA repair is indicated in an otherwise 
stable patient, CT offers more precise pre-operative planning via multiplanar 
orthogonal measurements.
2.7.2 Surveillance
Aside from baseline screening, AAA surveillance also plays a significant role in 
mortality reduction, by monitoring changes in AAA size over time and subsequent 
timely identification of patients whose risk of rupture begins to approach or out-
weigh the risks of intervention. Despite multiple large-scale clinical research trials 
comparing AAA size versus risk of rupture, vascular and radiology literature has 
yet to produce a single unifying surveillance parameter, but several evidence-based 
criteria allow patients to be safely observed over time despite a relatively small 
background risk of rupture. The SVS recently provided updated guidelines for the 
surveillance of patients with AAA, including recommended surveillance imag-
ing at 3-year intervals for patients with AAA between 3.0 and 3.9 cm in diameter, 
12-month intervals for 4.0–4.9 cm, and 6-month intervals for 5.0 and 5.4 cm [33]. 
The American College of Radiology (ACR) appropriateness criteria designates 
duplex ultrasound of the aorta/abdomen, CTA of the abdomen and pelvis with 
intravenous contrast, or MRA of the abdomen and pelvis with intravenous contrast 
as “usually appropriate” (a rating of 7, 8, or 9) for surveillance of asymptomatic 
AAA without previous repair [35].
The remaining aortic pathologies, including that of aortic dissection, present 
with a wide range of clinical, laboratory, and imaging findings, and therefore are 
similarly evaluated with CT or CT angiography for prompt diagnosis.
2.8 Treatment of AAA
2.8.1 Medical therapy
Hypertensive disease is the main major risk factor for aortic thoracic disease 
with genetic predisposition as second major risk factor [36, 37]. Although, this 
notion is based on studies mostly including Marfan disease patients [38]. For 
patients with asymptomatic AA, anti-hypertensive therapy with beta blockers is 
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recommended for blood pressure control with the goal being to limit aortic wall 
expansion. Angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers (ARBs) are preferred as well due to their role as modifiers of inflammatory 
mediators and by decreasing vascular smooth muscle apoptosis [38, 39].
Beta blockers have been the traditional treatment for thoracic aortic disease. 
It was originally demonstrated more than 70 years ago when turkeys eating 
sweet pea seed, Lathyrus odoratus, which contains the lysis oxidase inhibitor, 
B-aminopropionitrile, die of acute aortic dissections. The beta blocker propranolol 
was found to decrease deaths from dissection in B-aminopropionitrile fed turkeys 
[40–43]. Beta-blockers such as propranolol benefit the aortic wall through nega-
tive inotropic and chronotropic effects. Through these effects, the elastic fibers of 
the wall are protected from further damage and is further supported by reduction 
in left ventricular pressure of the heart and heart rate [44]. However, the benefit 
of beta-adrenergic blockade is better established in aortic dissection than in AAA 
because beta blockers provide theoretical benefit on blood pressure and left ven-
tricular pressure reduction [45].
Angiotensin converting enzyme inhibition may have a beneficial role by 
modifying inflammatory mediators and decreasing vascular smooth muscle 
apoptosis. Angiotensin receptor blockers such as Losartan have been shown to 
prevent expansion of aneurysms by downregulation of transforming growth 
factor B [38, 46, 47]. Angiotensin II type 1 receptor blockade within the renin-
angiotensin-aldosterone system causes a decrease in TGF-B signaling further 
reducing levels of intracellular mediators within the TGF-B signaling cascade, such 
as phosphorylated SMAD [37, 48]. By this mechanism, there is a reduced prolifera-
tion of vascular smooth-muscle cells, fibrosis, and expression of matrix metal-
loproteinases [49]. Overactivation of the angiotensin II type 2 receptor pathway 
by ARBs causes antiproliferative and anti-inflammatory effects that are beneficial 
in aortic wall homeostasis [50]. In contrast, ACE inhibitors limit the production 
of angiotensin II, producing a negative effect on Angiotensin II type 1 and type 2 
receptor pathways which do not influence alternative mechanisms [46].
Medical treatment with statins (3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors) power many of the inflammatory pathways of the formation 
of aortic aneurysms. Statins provide a protective effect by inhibition of matrix 
metalloproteinases (MMPs) and plasminogen activator due to the aforementioned 
proteolytic enzymes involved in the pathophysiology of aortic aneurysm formation 
[39, 51, 52].
2.8.2 Surgical and endovascular treatment
Historically, abdominal aortic aneurysm was treated with open surgical repair 
once aneurysmal growth reached a certain size or rate. Recent advancements have 
allowed endovascular repair to be used as the primary modality of repair with open 
surgical repair reserved for emergency/unconventional situations.
3. Genetic etiologies of aortic aneurysms and dissections
Genetics play an important role in the pathogenesis of various diseases. While 
multifactorial processes have been described in the development of AAA and AD, 
there are two Mendelian disorders which may lead to AAA or AD, Marfan syndrome 
and Ehlers-Danlos syndrome (EDS). Both have been connected to the development 
of AAs and ADs lacking classic risk factors such as smoking, hypertension, and old 
age. By definition, both of these syndromes result from mutations in a single gene 
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and inheritance pattern. Overall, both Marfan syndrome and EDS share deleterious 
effects on connective tissues in the body which consequently have major ramifica-
tions on the integrity of major blood vessels.
3.1 Ehlers-Danlos syndrome
Ehlers-Danlos syndromes (EDS) are a rare group of inherited disorders of col-
lagen which ultimately impair the integrity of the extracellular matrix of supporting 
structures such as connective tissues. Clinically, people with EDS usually feature 
remarkable hyperelastic skin, hypermobile joints, and often a bleeding diathesis. 
At least six clinical and genetic variants of EDS have been established and they 
all share a generalized defect in collagen, including abnormalities in its structure, 
synthesis, secretion and degradation.
In this discussion, the vascular subtype of EDS, previously referred to as type IV 
EDS, is the focus of this section. The vascular subtype of EDS (vEDS) is manifested 
from a key mutation affecting the COL3A1 gene, which subsequently causes defi-
cient synthesis of type III procollagen. The diagnosis of vEDS is made from major 
and minor clinical criteria and can be confirmed by abnormalities in procollagen 
production as seen in protein gel electrophoresis and molecular genetic testing.
3.1.1 Epidemiology of EDS
The incidence of vEDS is roughly 1:100,000 with a total of 1500 affected indi-
viduals in the United States having been identified on the basis of biochemical and 
genetic testing and analysis of family pedigrees [53].
3.1.2 Molecular genetics of EDS
The COL3A1 gene is found on chromosome locus 2q32.2 and encodes for type 
III pro-collagen. The COL3A1 is estimated to be over 44 kb in size [54]. The vEDS 
subtype is inherited in an autosomal dominant pattern.
3.1.3 Pathogenesis of EDS
Type III collagen is extremely prevalent in skin, vessel walls and reticular fibers 
of most tissues such as the lungs, liver, and spleen. Mutations in the COL3A1 gene 
responsible for vEDS can take various forms. These include point mutations, dele-
tions, insertions, splicing mutations, and missense mutations. The most common 
genetic mutation associated with vEDS is a missense mutation of a crucial glycine 
residue in the triple helical domain of the alpha-1 (III)-chains of type III procol-
lagen. The mutation almost always occurs in a particular region of the protein that is 
used to bind to other collagen proteins. Three collagen proteins always bind together 
into a trimer, which is required for collagen functionality; when not bound in a 
trimer, collagen is useless, as it cannot provide functional or structural support [55].
The most common missense mutation recognized in the literature is a substitu-
tion of glycine to glutamic acid or lysine (Glu>Lys), both leading to the production 
of a defective polypeptide and disrupted (Gly-X-Y)n collagen motif [56]. This leads 
to the development of severely malformed collagen fibrils and reticulin fibers in the 
extracellular matrix of dermal and arterial tissues.
Type III procollagen is a major structural protein in hollow organs and vessel 
walls. An altered structure of the protein makes it dysfunctional in large elastic 
arteries such as the aorta causing them to be more prone to rupture or dissection. 
The mechanisms by which mutant type III collagen molecules create vascular 
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fragility are not well understood in humans, though clinically vEDS is characterized 
by weakness of tissues rich in type III collagen, such as blood vessels, thus predis-
posing them to aneurysm and dissection [57].
3.2 Marfan syndrome
Marfan syndrome is caused by an inherited mutation of the FBN1 gene cod-
ing for the extracellular glycoprotein Fibrillin-1. The mutation in FBN1 initiates 
instability of connective tissue extracellular matrix, manifesting broadly as changes 
to the skeleton, eyes, and cardiovascular system. There have been more than 1800 
distinct causative mutations in the FBN1 gene which complicates the diagnosis by 
DNA sequencing alone. As a result, the diagnosis of Marfan syndrome is mainly 
based on clinical findings. Classically you will see ectopia lentis, tall stature with 
coinciding arachnodactyly, and hyperlaxity of joints.
3.2.1 Epidemiology of Marfan syndrome
The prevalence of Marfan syndrome is estimated to be 1 in 5000. According to 
National Human Genome Research Institute, roughly 75% of cases are familial and 
the remaining 25% of cases are a result of a new (de novo) mutation in the FBN1 
gene. In a 2015 study involving 412 people confirmed as having Marfan syndrome, 
the median age at diagnosis is found to be 19.0 years [58].
3.2.2 Molecular genetic of Marfan syndrome
Fibrillin-1 is encoded for by the FBN1 gene (chromosome locus 15q21) which is 
estimated to be 235 kb in size [59]. Marfan syndrome is inherited in an autosomal 
dominant pattern.
3.2.3 Pathogenesis of Marfan syndrome
Fibrillin-1 is secreted by fibroblasts, is modified post-translationally by glycosyl-
ation, and is the major component of microfibrils found in the extracellular matrix 
of connective tissue. Microfibrils are widely distributed in the body, more specifi-
cally they are abundant in the aorta, ligaments, and the ciliary zonules that support 
the ocular lens. This distribution of microfibrils gives rise to the unique clinical 
presentation classically known as Marfanoid habitus.
More recently, microfibril-associated glycoprotein 4 (MFAP4) has been linked to 
the pathogenesis of Marfan syndrome. Yin et al. using a glycoproteomic analysis of 
aortic extracellular matrix in Marfan patients, found an increased and more diverse 
N-glycosylation of MFAP4 in patients with Marfan syndrome compared with 
control patients. Most importantly in our discussion of AA and AD, this increased 
N-glycosylation was particularly in the aneurysmal stages [60, 61].
The defective Fibrillin-1 protein and subsequent faulty microfibrils are fun-
damental in the progression to an aortic aneurysm or an aortic dissection seen in 
Marfan syndrome. Not only do microfibrils provide structural integrity of specific 
organ systems, but they also provide a scaffold for elastogenesis in elastic tissues, 
most notably in elastic arteries such as the aorta [62]. In a way, malfunctioning 
FBN1 gene inserts malware into microfibrils, thus dismantling the scaffold needed 
for elastogenesis. This defective elasticity in the tunica media of elastic arteries such 
as the aorta weakens the vessel wall predisposing to early aneurysm. Weakening 
of the media also predisposes to any intimal tear, which may initiate an intramural 
hematoma that cleaves the layers of the media to produce aortic dissection.
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Interestingly, the loss of microfibrils also gives rise to abnormal and excessive 
activation of transforming growth factor-B (TGF-B). Normally sequestered by well-
functioning microfibrils, excessive TGF-B signaling has deleterious effects on both 
vascular smooth muscle development and the overall integrity of the extracellular 
matrix at a cellular level. Excessive TGF-B signaling in the adventitia of large elastic 
arteries causes increased deposition of weak fibrotic tissue leading to aneurysm 
development [58].
4. Conclusion
The pathogenesis of AAA formation is complex and multidimensional. The 
traditional atherosclerotic or inflammatory variant of AAA may be segmented 
into a process of proteolysis, inflammation, and VSMC apoptosis. Oxidative stress 
acts as a fulcrum throughout this process which is also involved in other acquired 
aortic pathologies such as mycotic aneurysm and aortic dissection. Classically, 
aortic pathology is affiliated with connective tissue disorders like seen in Marfan 
and Ehlers-Danlos syndromes. With further studies and eventual development, the 
understanding of AAA formation as well as other aortic pathologies will lead to addi-
tional treatment tools for vascular specialists and other healthcare providers alike.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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